New drugs approved for acute myeloid leukemia (AML) in 2018.

Clicks: 338
ID: 28451
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #10 of 44 articles by views in British journal of clinical pharmacology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Acute myeloid leukemia (AML) is a hematopoietic stem cell disorder, that is characterized by the clonal expansion of myeloid blasts and suppression of normal hematopoiesis. The 3+7 regimen is the backbone of standard first-line induction therapy among young/fit patients. However, in elderly and/or unfit patients with newly diagnosed AML, who cannot receive intensive chemotherapy, low-dose cytarabine (LDAC) or hypomethylating agents (HMAs; azacitidine or decitabine) are the treatment options, which generally cannot induce durable responses. Among young/fit patients, for high-risk disease in first remission, or in cases with relapsed/refractory AML (RRAML), allogeneic stem cell transplantation (ASCT) should be performed when complete remission is achieved. However, since AML is primarily a disease of the elderly, neither intensive chemotherapy nor ASCT can be generally tolerated in most cases. There is clearly a need for new treatment options in elderly and young/unfit patients who cannot receive intensive chemotherapy. The discovery of novel molecular genetic markers (e.g. FMS-like tyrosine kinase 3 (FLT3), isocitrate dehydrogenase 1 (IDH1), isocitrate dehydrogenase 2 (IDH2), etc.) resulted in the development of new therapeutic options in AML. This review mainly focuses on 4 targeted therapy agents; glasdegib and venetoclax used in combination treatment with LDAC or HMAs among newly diagnosed cases with AML and ivosidenib and gilteritinib as monotherapy in the treatment of RRAML, which were all approved by the United States Food and Drug Administration (FDA) in 2018.
Reference Key
kucukyurt2019newbritish Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kucukyurt, Selin;Eskazan, Ahmet Emre;
Journal British journal of clinical pharmacology
Year 2019
DOI
10.1111/bcp.14105
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.